NASDAQ:SVRA

Savara Stock Forecast, Price & News

$1.45

+0.09 (+6.62 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.30

Now: $1.45▼

$1.48

50-Day Range

$1.15

MA: $1.30▼

$1.47

52-Week Range

$1.00

Now: $1.45▼

$3.95

Volume759,671 shs

Average Volume396,804 shs

Market Capitalization$78.50 million

P/E RatioN/A

Dividend YieldN/A

Beta0.85

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

MarketRank^™

Overall MarketRank^™

1.60 out of 5 stars

Medical Sector

256th out of 1,558 stocks

Pharmaceutical Preparations Industry

135th out of 638 stocks

3.5 Analyst's Opinion

Consensus Rating
Savara has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Savara has a forecasted upside of 106.9% from its current price of $1.45.
Amount of Analyst Coverage
Savara has only been the subject of 2 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Savara has received 265 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Savara has received 285 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Savara has received 51.82% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Savara and other stocks. Vote “Outperform” if you believe SVRA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SVRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Savara does not currently pay a dividend.
Dividend Growth
Savara does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Savara insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.77% of the stock of Savara is held by insiders.
Percentage Held by Institutions
45.67% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Savara are expected to grow in the coming year, from ($0.77) to ($0.62) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Savara is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Savara is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Savara has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SVRA

Previous SymbolAMEX:ANX

CUSIPN/A

CIK1160308

Webwww.savarapharma.com

Phone512-614-1848

EmployeesN/A

Debt

Debt-to-Equity Ratio0.30

Current Ratio15.89

Quick Ratio15.89

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash Flow$6.30 per share

Price / Cash Flow0.23

Book Value$2.47 per share

Price / Book0.59

Profitability

EPS (Most Recent Fiscal Year)$4.57

Net Income$-78,170,000.00

Net MarginsN/A

Return on Equity-52.16%

Return on Assets-38.67%

Miscellaneous

Outstanding Shares54,141,000

Market Cap$78.50 million

Next Earnings Date3/11/2021 (Estimated)

OptionableOptionable

$1.45

+0.09 (+6.62 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive SVRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.

Savara (NASDAQ:SVRA) Frequently Asked Questions

How has Savara's stock price been impacted by COVID-19?

Savara's stock was trading at $2.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SVRA shares have decreased by 38.6% and is now trading at $1.45.
View which stocks have been most impacted by COVID-19.

Is Savara a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Savara stock.
View analyst ratings for Savara or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Savara?

Wall Street analysts have given Savara a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Savara wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Savara's next earnings date?

Savara is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Savara.

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) issued its quarterly earnings results on Thursday, November, 5th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The business had revenue of $0.26 million for the quarter.
View Savara's earnings history.

What price target have analysts set for SVRA?

2 equities research analysts have issued twelve-month price targets for Savara's stock. Their forecasts range from $3.00 to $3.00. On average, they anticipate Savara's stock price to reach $3.00 in the next year. This suggests a possible upside of 106.9% from the stock's current price.
View analysts' price targets for Savara or view Wall Street analyst' top-rated stocks.

Who are some of Savara's key competitors?

Some companies that are related to Savara include Alpine Immune Sciences (ALPN), KalVista Pharmaceuticals (KALV), Paratek Pharmaceuticals (PRTK), Kamada (KMDA), Fulcrum Therapeutics (FULC), Nature's Sunshine Products (NATR), Larimar Therapeutics (LRMR), Mustang Bio (MBIO), BELLUS Health (BLU), CorMedix (CRMD), Verrica Pharmaceuticals (VRCA), VYNE Therapeutics (VYNE), Lannett (LCI), RedHill Biopharma (RDHL) and Cassava Sciences (SAVA).
View all of SVRA's competitors.

What other stocks do shareholders of Savara own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CEL-SCI (CVM), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP).

Who are Savara's key executives?

Savara's management team includes the following people:

Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
David L. Lowrance, Chief Financial Officer (Age 50)
Nevan C. Elam, Independent Director (Age 49)
Richard J. Hawkins, Independent Director (Age 68)
Joseph S. McCracken Ph.D., Independent Director (Age 64)
Matthew Pauls J.D., Independent Director (Age 46)
Yuri Pikover, Independent Director (Age 56)

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

How do I buy shares of Savara?

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $1.45.

How big of a company is Savara?

Savara has a market capitalization of $78.50 million. The company earns $-78,170,000.00 in net income (profit) each year or $4.57 on an earnings per share basis.

What is Savara's official website?

The official website for Savara is www.savarapharma.com.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The company can be reached via phone at 512-614-1848 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here